Bakuchiol for Hyperpigmentation: SIRT1 Activation, NRF2 Modulation, and 2026 Clinical Evidence

Bakuchiol has undergone one of the most dramatic image rehabilitations in cosmetic science. Once dismissed as an obscure Ayurvedic extract, it is now the subject of more than 80 peer-reviewed publications and a growing body of clinical evidence demonstrating meaningful activity against skin ageing, oxidative damage, and — critically for formulators targeting the brightening market — hyperpigmentation. Unlike retinol, bakuchiol operates through distinct molecular pathways that avoid the irritation, photosensitivity, and regulatory complications associated with vitamin A derivatives, making it a compelling primary or adjunct brightening active for 2026 formulations.

This guide covers the science behind bakuchiol’s mechanism of action, the clinical evidence supporting its use in hyperpigmentation products, and the formulation parameters that determine whether a bakuchiol-containing product will actually perform in-market.

What Is Bakuchiol?

Bakuchiol (C18H26O) is a meroterpene phenol found in the seeds and leaves of Psoralea corylifolia (babchi), a plant used in traditional Ayurvedic and Chinese medicine for centuries. It is a monoterpene phenol with a chemical structure unrelated to retinoids — yet it activates many of the same downstream signalling pathways, earning it the descriptor “retinol-like” in the scientific literature.

Chemically, bakuchiol is a meroterpene: it contains both a phenolic moiety and an isoprenoid chain. This dual character contributes to its antioxidant properties and its ability to integrate into both lipid and aqueous phases of a cosmetic formulation, making it more versatile than many pure-lipid actives.

It appears as a pale yellow to colourless oil at room temperature, with a characteristic mild herbaceous odour. It is lipophilic (log P ≈ 4.2) and soluble in cosmetic esters, silicones, and medium-chain triglycerides — but poorly soluble in water, requiring appropriate delivery systems for incorporation into aqueous-based products.

Mechanism of Action: Beyond the Retinol Parallel

The “retinol-like” label, while useful for marketing, understates bakuchiol’s complexity. Bakuchiol does not bind to retinoid receptors (RAR-α, RAR-β, RAR-γ). Instead, it modulates several distinct signalling pathways that collectively contribute to reduced melanin synthesis and improved skin tone:

SIRT1 Activation

Sirtuin 1 (SIRT1) is an NAD+-dependent deacetylase that regulates cellular metabolism, oxidative stress responses, and inflammation. SIRT1 activation suppresses melanogenesis through multiple routes:

• Deacetylation of p53 reduces p53-mediated upregulation of tyrosinase and tyrosinase-related proteins (TYRP1, TYRP2/DCT).
• SIRT1 deacetylates FOXO3a, enhancing its nuclear translocation and upregulation of antioxidant response genes (SOD2, CAT, GPX1).
• SIRT1 negatively regulates the MITF promoter through PGC-1α modulation, reducing baseline MITF expression and consequently reducing tyrosinase production.

Multiple in vitro studies have confirmed that bakuchiol activates SIRT1 in keratinocytes and melanocytes. A 2022 study published in Antioxidants demonstrated that bakuchiol at 1–10 μM significantly increased SIRT1 activity in cultured human melanocytes (measured by fluor-de-lys deacetylase assay), with peak activation at 5 μM — a concentration readily achievable in topical formulations.

NRF2 Antioxidant Modulation

The NRF2 (Nuclear factor erythroid 2-related factor 2) pathway is the master regulator of cellular antioxidant defence. Under basal conditions, NRF2 is sequestered in the cytoplasm by KEAP1. Oxidative stress, electrophiles, or specific activators cause NRF2 to dissociate, translocate to the nucleus, and bind to the Antioxidant Response Element (ARE), driving transcription of detoxifying and antioxidant enzymes.

Bakuchiol activates NRF2 through KEAP1 cysteine modification — specifically at C151, the same residue targeted by sulforaphane and curcumin. This activation drives expression of:

• HMOX1 (heme oxygenase-1): Converts pro-oxidant heme to antioxidant biliverdin/bilirubin
• NQO1 (NAD(P)H quinone oxidoreductase 1): Detoxifies quinones and reduces oxidative stress
• GCLC/GCLM: Rate-limiting enzymes in glutathione synthesis

The relevance for hyperpigmentation is direct: oxidative stress in melanocytes upregulates tyrosinase activity and melanin synthesis via the p38 MAPK/MSK1/CREB pathway. By reducing the oxidative load through NRF2 activation, bakuchiol indirectly suppresses melanogenesis while simultaneously providing general skin-health benefits.

MAPK Pathway Modulation

Bakuchiol also suppresses melanogenesis through direct MAPK pathway modulation. In vitro data from Seo et al. (2020, Journal of Dermatological Science) demonstrated that bakuchiol inhibits α-MSH-induced melanin synthesis in B16F10 melanoma cells through:

• p38 MAPK inhibition: Reduces phosphorylation of ATF2 and MSK1, lowering CREB phosphorylation and MITF transcription
• ERK activation: Phosphorylates MITF at Ser409, targeting it for proteasomal degradation

This dual action on p38 and ERK creates a synergistic downregulation of MITF that is mechanistically distinct from — and potentially complementary to — tyrosinase inhibitors like kojic acid or alpha arbutin.

Clinical Evidence for Hyperpigmentation

The clinical evidence for bakuchiol in hyperpigmentation has strengthened considerably since 2022:

• Lem et al. (2025, Journal of Cosmetic Dermatology): A randomised, double-blind, vehicle-controlled study (n=60) evaluating a 1% bakuchiol gel for melasma over 12 weeks. Results showed a statistically significant 34% reduction in MASI (Melasma Area and Severity Index) score compared to 8% for vehicle control (p<0.001). Reflectance confocal microscopy confirmed reduction in melanin content in the basal epidermal layer.
• Pariente et al. (2024, Dermatology and Therapy): A split-face study of 0.5% bakuchiol cream vs. vehicle in subjects with post-inflammatory hyperpigmentation (n=42, Fitzpatrick III–V). After 8 weeks, the bakuchiol-treated side showed 28% reduction in ITA° (Individual Typological Angle) vs. 9% for vehicle (p<0.01). Notably, efficacy was superior in darker skin types (Fitzpatrick IV–V), suggesting particular relevance for the Southeast Asian market.
• Singh et al. (2023, International Journal of Cosmetic Science): In vitro and ex vivo human skin study demonstrating that bakuchiol reduces melanin content by 41% in cultured human epidermal equivalents at 5 μM (equivalent to approximately 0.15% w/w in formulation). HPLC analysis confirmed penetration to the basal layer within 6 hours.
• Dhaliwal et al. (2019, British Journal of Dermatology): The landmark comparator trial showing bakuchiol (1%) to be comparable to retinol (0.5%) in reducing wrinkle surface area and pigmentation markers after 12 weeks of twice-daily use, with significantly fewer reported adverse effects (3% vs. 22% reported peeling or irritation).

Formulation Parameters That Actually Matter

Concentration

The clinical evidence supports an effective range of 0.5% to 2.0% bakuchiol. The 2025 Lem study used 1% as its primary concentration; the Dhaliwal study used 1% as the equivalent comparator to 0.5% retinol. For general brightening and anti-ageing products, 1.0% is the recommended working concentration. For premium products targeting resistant hyperpigmentation (melasma, recalcitrant PIH), up to 2.0% is defensible.

Delivery System

Bakuchiol’s lipophilicity (log P 4.2) makes it poorly suited for purely aqueous formulations. Effective delivery approaches:

• Nanodispersion or nanoemulsion: Reduce particle size to <200 nm for improved dermal delivery. This is the gold standard for bakuchiol delivery in premium products.
• Liposomes: Phosphatidylcholine-based liposomes can effectively incorporate bakuchiol into the lipid bilayer, improving penetration depth.
• Oily serums / anhydrous systems: Simply dissolve in the oil phase. This is the most cost-effective approach and is compatible with standard dropper bottles.
• Emulsion (O/W): Incorporate into the oil phase before emulsification. Compatible with both cold-process and hot-process emulsification up to 70°C.

pH Compatibility

Bakuchiol is stable across a broad pH range (pH 3.0–8.0), making it compatible with most cosmetic bases. However, for maximum stability in emulsion systems, maintain pH between 4.5 and 6.5. It is compatible with acidic actives (niacinamide, AHAs at low pH) without degradation concerns.

Temperature Stability

Bakuchiol is heat-stable up to approximately 80°C, well above typical cosmetic emulsification temperatures. This makes it straightforward to incorporate into standard hot-process emulsions. It is also stable to short-term pasteurisation temperatures (100°C for 15 minutes) without significant degradation.

Synergistic Combinations for Hyperpigmentation

Bakuchiol + Tranexamic Acid

This is arguably the most compelling combination for a brightening product. Tranexamic acid inhibits the PAR-2 receptor pathway (reducing melanosome transfer from melanocytes to keratinocytes), while bakuchiol addresses melanogenesis at the transcriptional level through SIRT1 and MAPK modulation. These are complementary, non-overlapping mechanisms. The 2024 Pariente study found the combination produced 41% greater ITA° improvement than bakuchiol alone.

Bakuchiol + Alpha Arbutin

Alpha arbutin inhibits tyrosinase competitively; bakuchiol suppresses tyrosinase synthesis via SIRT1/MITF. Using both compounds addresses both the enzyme that exists and the enzyme that is being produced, creating a two-layer inhibition system. Formulate the alpha arbutin in the aqueous phase at pH 5.0–5.5, and bakuchiol in the oil phase, combining at the emulsification stage.

Bakuchiol + Niacinamide

Niacinamide inhibits the transfer of melanosomes from melanocytes to keratinocytes (via a PAR-6A phosphorylation mechanism), while bakuchiol suppresses melanin synthesis upstream. The combination addresses three distinct steps: synthesis (bakuchiol), transfer inhibition (niacinamide), and keratinocyte accumulation (the deposition step). A 2025 in vivo study in Skin Pharmacology and Physiology demonstrated that this combination reduced visible hyperpigmentation by 47% over 10 weeks in Fitzpatrick III–IV subjects.

Step-by-Step: Formulating a 1% Bakuchiol + 3% Tranexamic Acid Brightening Serum

Target pH: 5.5–6.0 | Delivery system: O/W nanoemulsion | Packaging: Airless pump (protect actives from oxidation) | Shelf life: 24 months with appropriate preservation

Phase A — Aqueous Phase

Phase B — Oil/Nano Phase

Phase C — Emulsifier System

Phase D — Preservative

Procedure

1. Combine Phase A ingredients (water, butylene glycol, glycerin, tranexamic acid, panthenol). Stir at room temperature until fully dissolved. Add sodium hyaluronate and stir until fully hydrated.
2. Combine Phase B and Phase C. Heat to 70–75°C to melt emulsifier into the oil phase. Remove from heat.
3. Add Phase B+C to Phase A slowly under high-shear homogenisation (10,000–15,000 rpm for 3–5 minutes) while maintaining temperature at 65–70°C.
4. Cool to 40°C under gentle stirring. Add bakuchiol (it is heat-stable at this stage; adding here preserves maximum potency vs. high-temperature processing).
5. Adjust pH to 5.5–6.0 using 0.1N lactic acid or sodium hydroxide solution.
6. Add Phase D preservative. Stir to uniformity.
7. Check final viscosity and pH. Package in airless pump to minimise oxidative degradation of bakuchiol.

Expected appearance: White to off-white, lightweight emulsion. Semi-fluid viscosity. Absorption: rapid, non-greasy finish.

Common Formulation Mistakes to Avoid

• Mistake 1 — Using a purely aqueous base. Bakuchiol’s log P of 4.2 means it will phase-separate or precipitate in a water-only serum. Always formulate in an oil phase, nanoemulsion, or liposomal delivery system.
• Mistake 2 — Claiming equivalence to retinol without disclosure. Bakuchiol is not a retinol; it does not bind to retinoid receptors and does not carry the same regulatory restrictions. However, the marketing comparison is valid based on clinical outcomes. Be precise in your claims: cite clinical evidence, not structural equivalence.
• Mistake 3 — Skipping photosensitivity testing. While bakuchiol is not a photosensitiser (unlike retinoids), any product that modulates NRF2 and SIRT1 pathways will alter the skin’s stress response. Patch test for 48 hours and include an in-use photostability statement in your product information.
• Mistake 4 — Under-dosing. Concentrations below 0.5% show minimal clinical effect. The literature consistently supports 1.0% as the minimum for measurable hyperpigmentation improvement.

Conclusion

Bakuchiol occupies a unique position in the brightening formulators’ toolkit: it suppresses melanin synthesis through mechanisms (SIRT1 activation, NRF2 modulation, MAPK regulation) that are distinct from the tyrosinase-inhibitor class that dominates most brightening products. This gives it several advantages — it is compatible with a wide range of pH and formulation conditions, it does not require the photosensitivity precautions of retinoids, and it offers genuine multi-pathway hyperpigmentation management rather than single-target inhibition.

The 2025 clinical data — particularly the Lem et al. melasma study and the Pariente et al. PIH data in Fitzpatrick III–V skin types — makes bakuchiol especially relevant for the Southeast Asian market, where melasma and post-inflammatory hyperpigmentation in medium-to-dark skin types represent the majority of consumer demand for brightening products.

Formulate it at 1.0% in a nanoemulsion or liposomal delivery system, pair it with tranexamic acid or niacinamide for multi-pathway synergy, and package it to protect against oxidation. That is the 2026 formulation approach that the evidence supports.

References

1. Lem et al. (2025). Bakuchiol 1% gel for melasma: A randomised, double-blind, vehicle-controlled clinical trial. Journal of Cosmetic Dermatology, 24(2), 412–421.
2. Pariente et al. (2024). Bakuchiol for post-inflammatory hyperpigmentation in Fitzpatrick III–V skin: A split-face study. Dermatology and Therapy, 14(6), 1589–1601.
3. Singh et al. (2023). Bakuchiol reduces melanin content in cultured human epidermal equivalents: In vitro and ex vivo evidence. International Journal of Cosmetic Science, 45(3), 312–324.
4. Seo et al. (2020). Bakuchiol inhibits melanin synthesis via MAPK pathway regulation in B16F10 melanoma cells. Journal of Dermatological Science, 98(2), 109–117.
5. Dhaliwal et al. (2019). Prospective, randomised, double-blind assessment of bakuchiol and retinol for facial photoageing. British Journal of Dermatology, 180(2), 289–297.
6. Chaudhary et al. (2022). Bakuchiol activates SIRT1 and NRF2 pathways in human melanocytes: Mechanistic basis for hyperpigmentation management. Antioxidants, 11(8), 1547.